Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091988 | 0.84 | PLAU (0.43) | PLAULMNAL3MBTL1 | |
| SCHEMBL23706067 | 0.84 | PLAU (0.43) | PLAULMNAL3MBTL1 | |
| SCHEMBL30481308 | 0.81 | PLAU (0.43) | PLAULMNA | |
| SCHEMBL20188949 | 0.81 | PLAU (0.43) | PLAULMNA | |
| SCHEMBL25224414 | 0.81 | PLAU (0.43) | PLAULMNA | |
| SCHEMBL8866071 | 0.80 | PLAU (0.40) | PLAU | |
| SCHEMBL18378745 | 0.79 | PLAU (0.42) | PLAULMNA | |
| SCHEMBL19534297 | 0.79 | PLAU (0.46) | PLAUNOTUM | |
| SCHEMBL990259 | 0.78 | PLAU (0.47) | PLAULMNAL3MBTL1RECQLTDP1 | |
| Hydrochloric Acid SCHEMBL20399974 | 0.78 | PLAU (0.44) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119212994-A | Pyrazolopyrazine compounds as SHP2 inhibitors | 建新公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-113874363-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024218499-A1 | HETEROCYCLIC INHIBITORS OF DNA POLYMERASE THETA FOR THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2024-10-24 | — | — | WO | disclosed |
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220251083-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3947367-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | Array Biopharma, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113874363-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2020201991-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | PLAU 3585/4885LMNA 3344/4885L3MBTL1 2686/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PLAU 3585/4885LMNA 3344/4885L3MBTL1 2686/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | PLAU 4311/4885LMNA 4830/4885L3MBTL1 3713/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PLAU 3585/4885LMNA 3344/4885L3MBTL1 2686/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | PLAU 3585/4885LMNA 3344/4885L3MBTL1 2686/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | PLAU 3062/4885LMNA 225/4885L3MBTL1 1010/4885 |
| US-20220251083-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | PLAU 3585/4885LMNA 3344/4885L3MBTL1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.